Carcinotech

About

Carcinotech is a MedTech company based in Edinburgh, UK, founded in 2018. It specializes in solid-tumor research services and personalized cancer therapy. As a biotechnology research and development organization, Carcinotech aims to accelerate drug discovery and development by partnering with drug developers to create innovative cancer models. The company offers preclinical oncology services, focusing on advancing drug development and enabling personalized therapy decisions. Its primary product is 3D-printed mini tumors developed from patient-specific cancer data. By combining 3D bioprinting technology with patient data, Carcinotech creates tumor models that provide deeper insights into cancer biology and facilitate faster drug development. Headquartered at the Roslin Innovation Centre in Edinburgh, Carcinotech has strong connections to the University of Edinburgh and utilizes advanced lab facilities. The company has established licensing deals with notable pharmaceutical and biotech organizations, including AstraZeneca and GSK, to further enhance drug discovery and cancer treatment development.